New hope for stroke patients: drug may work up to 24 hours later
NCT ID NCT07606807
First seen Jun 01, 2026 · Last updated Jun 13, 2026 · Updated 2 times
Summary
This study tests a drug called tenecteplase (TNK) for people who have had a stroke caused by a blood clot in the brain. The drug is given up to 24 hours after symptoms start, using only a simple CT scan to decide who can get it. The goal is to see if TNK helps people recover better than standard care. The study will include 750 adults with moderate to severe stroke symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.